MedTrace Logo

Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study

NCT01451372 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2019-02-27

Study results available
· View outcomes & findings →

Summary

The aim of this study is to document the routine practice in continuous glucose monitoring (CGM) in patients treated with sensor-augmented pump therapy and to assess clinical outcome (HbA1c) before the start of the sensor use to the end of the follow-up period. Moreover, data on treatment satisfaction, and fear of hypoglycemia, cost of the therapy, side effects and treatment interruption will be collected.

Conditions

Sponsors & Collaborators

  • Medtronic Diabetes

    lead INDUSTRY

Principal Investigators

  • Eva Örtqvist, MD · ALB, Karolinska Universitetssjukhuset Solna

Eligibility

Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01451372 on ClinicalTrials.gov